Excluding metastatic deposits with primary tumors at these sites, which represented a substantial fraction of the visceral metastases (n = 9), from the analysis, moderated the difference observed (leaving 3/13 visceral deposits from cutaneous melanomas harboring BRAF mutations; 23.1 %), still, a significant difference in mutation distribution between metastases located to different organ systems remained (p = 0.040). The gene discussed is BRAF; the disease is cutaneous melanoma.